

# Raymund R Razonable

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/118677/publications.pdf>

Version: 2024-02-01

206  
papers

10,421  
citations

26630

56  
h-index

40979

93  
g-index

216  
all docs

216  
docs citations

216  
times ranked

9191  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons. <i>Clinical Infectious Diseases</i> , 2023, 76, e537-e539.	5.8	53
2	Unexpected Cytomegalovirus (CMV) Replication Kinetics in CMV Donor-Seropositive, Recipient-Seronegative Liver Transplant Recipients Receiving Preemptive Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2022, 225, 436-442.	4.0	6
3	Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities. <i>Journal of Infectious Diseases</i> , 2022, 225, 598-602.	4.0	40
4	Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19. <i>Mayo Clinic Proceedings</i> , 2022, 97, 26-30.	3.0	22
5	Successful Liver Transplantation From a SARS-CoV-2 Positive Donor to a Positive Recipient. <i>Transplantation</i> , 2022, Publish Ahead of Print, .	1.0	6
6	COVID-19 and Solid Organ Transplantation: Role of Anti-SARS-CoV-2 Monoclonal Antibodies. <i>Current Transplantation Reports</i> , 2022, 9, 26-34.	2.0	16
7	Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	20
8	Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19). <i>Obstetrics and Gynecology</i> , 2022, 139, 616-618.	2.4	21
9	Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant. <i>Mayo Clinic Proceedings</i> , 2022, 97, 327-332.	3.0	17
10	Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. <i>Mayo Clinic Proceedings</i> , 2022, 97, 943-950.	3.0	4
11	Cytomegalovirus-related Complications and Management in Facial Vascularized Composite Allotransplantation: An International Multicenter Retrospective Cohort Study. <i>Transplantation</i> , 2022, 106, 2031-2043.	1.0	5
12	Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	8
13	First-generation oral antivirals against SARS-CoV-2. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1230-1235.	6.0	21
14	Immune reconstitution inflammatory syndrome in a non-HIV immunocompromised patient with <i>Pneumocystis jirovecii</i> pneumonia. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	1
15	Twice as nice: <i>Cytomegalovirus</i> tele-education. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	2
16	Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019. <i>Journal of Patient Experience</i> , 2022, 9, 237437352211056.	0.9	1
17	Stewardship of COVID-19 volunteers by nested trial design. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1400-1401.	9.1	1
18	A consensus conference to define the utility of advanced infectious disease diagnostics in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 3150-3169.	4.7	16

#	ARTICLE	IF	CITATIONS
19	Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	28
20	Risk Factors for Cytomegalovirus Viremia following Liver Transplantation With a Seropositive Donor and Seronegative Recipient Receiving Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2021, 223, 1073-1077.	4.0	3
21	Absolute lymphocyte count as marker of cytomegalovirus and allograft rejection: Is there a "Safe Corridor" after kidney transplantation?. <i>Transplant Infectious Disease</i> , 2021, 23, e13489.	1.7	19
22	A rare manifestation of CMV disease in a kidney transplant recipient. <i>Transplant Infectious Disease</i> , 2021, 23, e13527.	1.7	1
23	Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19. <i>Journal of Primary Care and Community Health</i> , 2021, 12, 215013272110192.	2.1	40
24	Prosthetic Joint Infections Due to <i>Histoplasma capsulatum</i> : A Report of 3 Cases. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2021, 5, 225-229.	2.4	6
25	Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research. <i>Mayo Clinic Proceedings</i> , 2021, 96, 601-618.	3.0	20
26	Infection prevention and control considerations for safe outpatient monoclonal antibody infusions in patients with coronavirus disease 2019 (COVID-19). <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-2.	1.8	2
27	The Impact of Antifungal Prophylaxis in Lung Transplant Recipients. <i>Annals of the American Thoracic Society</i> , 2021, 18, 468-476.	3.2	10
28	A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 868-873.	2.6	24
29	Predictors of CMV Infection in CMV-Seropositive Kidney Transplant Recipients: Impact of Pretransplant CMV-Specific Humoral Immunity. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab199.	0.9	11
30	Fungal Infection in Lung Transplantation. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 471-482.	2.1	8
31	A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1250-1261.	3.0	45
32	Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab255.	0.9	56
33	Transient Hepatitis B Surface Antigenemia Following Immunization with Heplisav-B. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2021, 5, 542-547.	2.4	2
34	Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2021, 224, 1278-1286.	4.0	77
35	Reply to Puing et al. <i>Journal of Infectious Diseases</i> , 2021, , .	4.0	2
36	Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. <i>EClinicalMedicine</i> , 2021, 40, 101102.	7.1	116

#	ARTICLE	IF	CITATIONS
37	Individualized management of cytomegalovirus in solid organ transplant recipients. Expert Review of Precision Medicine and Drug Development, 2021, 6, 333-344.	0.7	2
38	Virtual Recruitment Is Here to Stay: A Survey of ID Fellowship Program Directors and Matched Applicants Regarding Their 2020 Virtual Recruitment Experiences. Open Forum Infectious Diseases, 2021, 8, ofab383.	0.9	15
39	Fungal Infection and Prevention in Lung Transplant. Current Fungal Infection Reports, 2021, 15, 136-142.	2.6	0
40	Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19. Journal of Clinical Investigation, 2021, 131, .	8.2	40
41	A tale of two unusual anaerobic bacterial infections in an immunocompetent man: A case report and literature review. Anaerobe, 2021, 71, 102416.	2.1	3
42	The limits of refusal: An ethical review of solid organ transplantation and vaccine hesitancy. American Journal of Transplantation, 2021, 21, 2637-2645.	4.7	26
43	Education of Infectious Diseases Fellows During the COVID-19 Pandemic Crisis: Challenges and Opportunities. Open Forum Infectious Diseases, 2021, 8, ofaa583.	0.9	4
44	Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B.1.617.2 (Delta) surge. Journal of Clinical Virology, 2021, 145, 105026.	3.1	29
45	Differences in Duration and Degree of Cytomegalovirus DNAemia Observed With Two Standardized Quantitative Nucleic Acid Tests and Implications for Clinical Care. Journal of Infectious Diseases, 2020, 221, 251-255.	4.0	8
46	Prevention and treatment of tuberculosis in solid organ transplant recipients. Expert Review of Anti-Infective Therapy, 2020, 18, 63-73.	4.4	14
47	In replyâ€”The â€œPerfect Cytokine Stormâ€•of COVID-19. Mayo Clinic Proceedings, 2020, 95, 2037-2038.	3.0	3
48	Avoiding a Medical Education Quarantine During the Pandemic. Mayo Clinic Proceedings, 2020, 95, S63-S65.	3.0	10
49	GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia. Mayo Clinic Proceedings, 2020, 95, 2382-2394.	3.0	77
50	Clinical Guidance and the Delivery of Care for Patients With Coronavirus Disease 2019. Mayo Clinic Proceedings, 2020, 95, S23-S25.	3.0	4
51	A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease 2019 in the Hospital Setting. Mayo Clinic Proceedings, 2020, 95, 1467-1481.	3.0	21
52	Antifungal prophylaxis in lung transplant recipients: A systematic review and metaâ€•analysis. Transplant Infectious Disease, 2020, 22, e13333.	1.7	17
53	Clinical Diagnostic Testing for Human Cytomegalovirus Infections. Journal of Infectious Diseases, 2020, 221, S74-S85.	4.0	47
54	Rapid Appraisal System for COVID-19 Medical Information. Mayo Clinic Proceedings, 2020, 95, S26-S28.	3.0	3

#	ARTICLE	IF	CITATIONS
55	Treatment Considerations for COVID-19. Mayo Clinic Proceedings, 2020, 95, 1454-1466.	3.0	79
56	Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors. JAMA - Journal of the American Medical Association, 2020, 323, 1378.	7.4	103
57	Cytomegalovirus in Solid Organ Transplant Recipients: Clinical Updates, Challenges and Future Directions. Current Pharmaceutical Design, 2020, 26, 3497-3506.	1.9	9
58	Association of HHV-6 With Outcomes in CMV-Seronegative Liver Transplant Recipients With CMV-Seropositive Donors Receiving Preemptive Antiviral Therapy. Transplantation, 2020, Publish Ahead of Print, 2427-2434.	1.0	2
59	Clinical Correlation of Cytomegalovirus Infection With CMV-specific CD8+ T-cell Immune Competence Score and Lymphocyte Subsets in Solid Organ Transplant Recipients. Transplantation, 2019, 103, 832-838.	1.0	29
60	Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. Clinical Infectious Diseases, 2019, 68, 1420-1426.	5.8	136
61	Long-term Outcomes of Patients With Human Herpesvirus 6 Encephalitis. Open Forum Infectious Diseases, 2019, 6, ofz269.	0.9	11
62	A Fatal Case of Disseminated Microsporidiosis Due to Anncaliia algerae in a Renal and Pancreas Allograft Recipient. Open Forum Infectious Diseases, 2019, 6, ofz285.	0.9	11
63	Herpes Simplex Viruses 1 and 2, Varicella Zoster Virus, and Human Herpes Viruses 6, 7, and 8 in Transplant Recipients. , 2019, , 667-677.		0
64	&lt;p&gt;Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review&lt;/p&gt;. Infection and Drug Resistance, 2019, Volume 12, 1481-1491.	2.7	88
65	Treatment of latent TB Infection and the risk of tuberculosis after solid organ transplantation: Comprehensive review. Transplant Infectious Disease, 2019, 21, e13178.	1.7	17
66	Application of a New Paradigm for Cytomegalovirus Disease Prevention in Mayo Clinicâ€™s First Face Transplant. Mayo Clinic Proceedings, 2019, 94, 166-170.	3.0	15
67	Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation. Expert Opinion on Drug Safety, 2019, 18, 1017-1030.	2.4	29
68	Antifungal prophylaxis in lung transplant: A survey of United States' transplant centers. Clinical Transplantation, 2019, 33, e13630.	1.6	31
69	Cytomegalovirus in solid organ transplant recipientsâ€™Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation, 2019, 33, e13512.	1.6	418
70	Why do lung transplant patients discontinue triazole prophylaxis?. Transplant Infectious Disease, 2019, 21, e13067.	1.7	19
71	Relationship of Ganciclovir Therapeutic Drug Monitoring with Clinical Efficacy and Patient Safety. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	39
72	A survey of infection prevention and control practices among solid organ transplantation centers. American Journal of Infection Control, 2019, 47, 101-104.	2.3	5

#	ARTICLE	IF	CITATIONS
73	<i>Mycobacterium tuberculosis</i> after solid organ transplantation: A review of more than 2000 cases. <i>Clinical Transplantation</i> , 2018, 32, e13259.	1.6	65
74	Travelerâ€™s Diarrhea Recommendations for Solid Organ Transplant Recipients and Donors. <i>Transplantation</i> , 2018, 102, S35-S41.	1.0	8
75	Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2018, 66, 617-631.	5.8	67
76	<sc>HHV</sc>â€6 in liver transplantation: A literature review. <i>Liver International</i> , 2018, 38, 210-223.	3.9	36
77	Cytomegalovirus (<sc>CMV</sc>) <sc>DNA</sc> quantification in bronchoalveolar lavage fluid of immunocompromised patients with <sc>CMV</sc> pneumonia. <i>Clinical Transplantation</i> , 2018, 32, e13149.	1.6	27
78	LB21. Preemptive Therapy (PET) vs. Prophylaxis for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Donor Seropositive/Recipient Seronegative (D+Râ€™) Liver Transplant Recipients (LTR): A NIH-Sponsored, Randomized, Controlled, Multicenter Trial. <i>Open Forum Infectious Diseases</i> , 2018, 5, S766-S766.	0.9	5
79	Absolute Lymphocyte Count Thresholds: A Simple, Readily Available Tool to Predict the Risk of Cytomegalovirus Infection After Transplantation. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy230.	0.9	37
80	An update on <i>Mycobacterium tuberculosis</i> infection after hematopoietic stem cell transplantation in adults. <i>Clinical Transplantation</i> , 2018, 32, e13430.	1.6	12
81	Drug-resistant cytomegalovirus: clinical implications of specific mutations. <i>Current Opinion in Organ Transplantation</i> , 2018, 23, 388-394.	1.6	53
82	Anti-infective chemoprophylaxis after solid-organ transplantation. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 469-479.	3.0	2
83	New Developments in the Management of Cytomegalovirus Infection After Transplantation. <i>Drugs</i> , 2018, 78, 1085-1103.	10.9	84
84	Donor derived <i>Mycobacterium tuberculosis</i> infection after solidâ€organ transplantation: A comprehensive review. <i>Transplant Infectious Disease</i> , 2018, 20, e12971.	1.7	51
85	Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 773-788.	3.1	14
86	Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 286-291.	3.1	18
87	Epidemiology and risk factors for infection after living donor liver transplantation. <i>Liver Transplantation</i> , 2017, 23, 465-477.	2.4	32
88	Progress Toward HHV-8 Prevention After Transplantation. <i>Transplantation</i> , 2017, 101, 1751-1752.	1.0	1
89	Evaluation of COBAS AmpliPrep/COBAS TaqMan CMV Test for use in hematopoietic stem cell transplant recipients. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 633-639.	3.1	6
90	Fungal Infections After Lung Transplantation. <i>Clinics in Chest Medicine</i> , 2017, 38, 511-520.	2.1	44

#	ARTICLE	IF	CITATIONS
91	Epidemiology, risk factors, and outcomes of infections in patients undergoing liver transplantation for hilar cholangiocarcinoma. <i>Clinical Transplantation</i> , 2017, 31, e13023.	1.6	8
92	How do we treat human herpesvirus 6 infection after allogeneic hematopoietic stem cell transplantation?. <i>Future Virology</i> , 2017, 12, 85-88.	1.8	0
93	Epidemiology, risk factors, and outcome of <i>Clostridium difficile</i> infection in heart and lung transplant recipients. <i>Clinical Transplantation</i> , 2017, 31, e12968.	1.6	15
94	Comparison of Standardized Cytomegalovirus (CMV) Viral Load Thresholds in Whole Blood and Plasma of Solid Organ and Hematopoietic Stem Cell Transplant Recipients with CMV Infection and Disease. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx143.	0.9	31
95	Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.. <i>Clinical Infectious Diseases</i> , 2017, 64, 87-91.	5.8	686
96	Cytomegalovirus DNA in Transplant Recipients: Comparison of Whole Blood and Plasma Viral Loads. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	1
97	Survey of Infection Prevention and Control (IPAC) Practices among Kidney and Liver Transplant Centers. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
98	Utilization of Quantiferon-Cytomegalovirus Assay to Assess the Risk of CMV Disease and Guide Duration of Antiviral Prophylaxis in CMV-Mismatched Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
99	Epidemiology and Risk Factors for Infection after Living Donor Liver Transplantation (LDLT). <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
100	Survey of Infection Prevention and Control (IPAC) Practices among Heart and Lung Transplant Centers. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
101	Cytomegalovirus (CMV) Deoxyribonucleic Acid (DNA) Quantification in Bronchoalveolar Lavage Fluid Collected From Immunocompromised Patients With CMV Pneumonia. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
102	Treatment of cytomegalovirus infection and disease pre- and post-quantitative nucleic acid test standardization: does use of a more sensitive assay lead to longer treatment duration?. <i>Clinical Transplantation</i> , 2016, 30, 154-160.	1.6	8
103	<i>Mycoplasma hominis</i> vertebral spine infection: Case report and a review of infections of bone and joints. <i>Journal of Infection and Chemotherapy</i> , 2016, 22, 755-758.	1.7	8
104	Cytomegalovirus. <i>Microbiology Spectrum</i> , 2016, 4, .	3.0	91
105	± Herpes Virus Infections Among Renal Transplant Recipients. <i>Seminars in Nephrology</i> , 2016, 36, 344-350.	1.6	15
106	Not the Usual Viral Suspects: Parvovirus B19, West Nile Virus, and Human T-Cell Lymphotropic Virus Infections After Kidney Transplantation. <i>Seminars in Nephrology</i> , 2016, 36, 428-434.	1.6	6
107	Non-tuberculous mycobacterial infections in solid organ transplant recipients: An update. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2016, 4, 1-8.	1.3	34
108	Cytomegalovirus Infection After Solid Organ Transplantation. , 2016, , 441-475.		2

#	ARTICLE	IF	CITATIONS
109	Clinical utility of cytomegalovirus viral load in solid organ transplant recipients. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 317-322.	3.1	23
110	Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus. <i>Infection and Drug Resistance</i> , 2015, 8, 269.	2.7	61
111	Epidemiology of invasive fungal infections in lung transplant recipients on long-term azole antifungal prophylaxis. <i>Clinical Transplantation</i> , 2015, 29, 311-318.	1.6	49
112	Risk factors for cytomegalovirus reactivation after liver transplantation: Can pre-transplant cytomegalovirus antibody titers predict outcome?. <i>Liver Transplantation</i> , 2015, 21, 539-546.	2.4	21
113	Predictors of Immune Reconstitution Syndrome in Organ Transplant Recipients With Cryptococcosis: Implications for the Management of Immunosuppression. <i>Clinical Infectious Diseases</i> , 2015, 60, 36-44.	5.8	79
114	Early CMV Infection Detected By Quantitative Nucleic Acid Testing (QNAT) Is Associated with Lower Risk of Relapse after Reduced Intensity, but Not Myeloablative, Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1913-1913.	1.4	0
115	Cytomegalovirus infection in liver transplant recipients: Updates on clinical management. <i>World Journal of Gastroenterology</i> , 2014, 20, 10658.	3.3	53
116	Management of cytomegalovirus infection and disease in liver transplant recipients. <i>World Journal of Hepatology</i> , 2014, 6, 370.	2.0	60
117	1174 Comparing the Duration of Treatment for Cytomegalovirus Infection Pre and Post Quantitative Nucleic Acid Test Standardization: Does Use of a More Sensitive Assay Lead to Longer Treatment Duration?. <i>Open Forum Infectious Diseases</i> , 2014, 1, S350-S350.	0.9	0
118	1426 Correlation of Cytomegalovirus Viral Load between a Laboratory-Developed Test and a WHO-Calibrated Commercial Assay in Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2014, 1, S375-S375.	0.9	1
119	Impact of urinary tract infection on allograft function after kidney transplantation. <i>Clinical Transplantation</i> , 2014, 28, 683-690.	1.6	78
120	Immune-based monitoring for cytomegalovirus infection in solid organ transplantation: is it ready for clinical primetime?. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1213-1227.	3.0	14
121	HHV-6A and HHV-6B in Solid Organ Transplantation. , 2014, , 201-215.		4
122	Editorial Commentary: Viridans Group Streptococci in Febrile Neutropenic Cancer Patients: What Should We Fear?. <i>Clinical Infectious Diseases</i> , 2014, 59, 231-233.	5.8	21
123	Reduction in False-Positive Aspergillus Serum Galactomannan Enzyme Immunoassay Results Associated with Use of Piperacillin-Tazobactam in the United States. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2199-2201.	3.9	55
124	Misidentification of <i>Neosartorya pseudofischeri</i> as <i>Aspergillus fumigatus</i> in a Lung Transplant Patient. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2722-2725.	3.9	16
125	Prolonged shedding of pandemic influenza A (H1N1) 2009 virus in a pancreas-after-kidney transplant recipient. <i>Journal of Clinical Virology</i> , 2014, 61, 302-304.	3.1	8
126	Clinical Utility of Viral Load in Management of Cytomegalovirus Infection after Solid Organ Transplantation. <i>Clinical Microbiology Reviews</i> , 2013, 26, 703-727.	13.6	179

#	ARTICLE	IF	CITATIONS
127	Management Strategies for Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients. <i>Infectious Disease Clinics of North America</i> , 2013, 27, 317-342.	5.1	51
128	Virologic Suppression Measured by a Cytomegalovirus (CMV) DNA Test Calibrated to the World Health Organization International Standard Is Predictive of CMV Disease Resolution in Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2013, 56, 1546-1553.	5.8	79
129	Cytomegalovirus Infections in Solid Organ Transplantation: A Review. <i>Infection and Chemotherapy</i> , 2013, 45, 260.	2.3	249
130	Urinary tract infections in kidney transplant recipients: Role of gender, urologic abnormalities, and antimicrobial prophylaxis. <i>Annals of Transplantation</i> , 2013, 18, 195-204.	0.9	79
131	Homozygosity for the Toll-Like Receptor 2 R753Q Single-Nucleotide Polymorphism Is a Risk Factor for Cytomegalovirus Disease After Liver Transplantation. <i>Journal of Infectious Diseases</i> , 2012, 205, 639-646.	4.0	60
132	Immune response to CMV in solid organ transplant recipients: current concepts and future directions. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 383-393.	3.0	26
133	Cytomegalovirus in Solid Organ Transplantation: Epidemiology, Prevention, and Treatment. <i>Current Infectious Disease Reports</i> , 2012, 14, 633-641.	3.0	107
134	Chromosomally integrated human herpesvirus 6: questions and answers. <i>Reviews in Medical Virology</i> , 2012, 22, 144-155.	8.3	320
135	Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review. <i>Transplant International</i> , 2012, 25, 493-502.	1.6	89
136	Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus. <i>Mayo Clinic Proceedings</i> , 2011, 86, 1009-1026.	3.0	203
137	Management of viral infections in solid organ transplant recipients. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 685-700.	4.4	29
138	Functional assessment of Toll-like receptor 2 and its relevance in patients with <i>Staphylococcus aureus</i> infection of joint prosthesis. <i>Human Immunology</i> , 2011, 72, 47-53.	2.4	17
139	Epidemiology of Cytomegalovirus Infection After Pancreas Transplantation. <i>Transplantation</i> , 2011, 92, 1044-1050.	1.0	22
140	Clinical Significance of Pretransplant Chromosomally Integrated Human Herpesvirus-6 in Liver Transplant Recipients. <i>Transplantation</i> , 2011, 92, 224-229.	1.0	44
141	Impact of Gram-Negative Bloodstream Infection on Long-Term Allograft Survival After Kidney Transplantation. <i>Transplantation</i> , 2011, 91, 1206-1210.	1.0	34
142	Human Herpes Virus 8 in Solid Organ Transplantation. <i>Transplantation</i> , 2011, 92, 837-844.	1.0	63
143	Reply to "May the Indirect Effects of CIHHV-6 in Transplant Patients be Exerted Through the Reactivation of the Viral Replicative Machinery?" <i>Transplantation</i> , 2011, 92, e51-e52.	1.0	0
144	Infections in liver transplant recipients. <i>World Journal of Hepatology</i> , 2011, 3, 83.	2.0	133

#	ARTICLE	IF	CITATIONS
145	Critical care issues in patients after liver transplantation. <i>Liver Transplantation</i> , 2011, 17, 511-527.	2.4	81
146	Spectrum of early-onset and late-onset bacteremias after liver transplantation: Implications for management. <i>Liver Transplantation</i> , 2011, 17, 733-741.	2.4	63
147	Toll-like receptor 2 polymorphism and Gram-positive bacterial infections after liver transplantation. <i>Liver Transplantation</i> , 2011, 17, n/a-n/a.	2.4	14
148	Chromosomally integrated human herpesvirus-6 in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2391-2393.	0.7	20
149	Rare, unusual, and less common virus infections after organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2011, 16, 580-587.	1.6	17
150	Fluoride Excess and Periostitis in Transplant Patients Receiving Long-Term Voriconazole Therapy. <i>Clinical Infectious Diseases</i> , 2011, 52, 604-611.	5.8	114
151	The impact of invasive fungal diseases on survival after lung transplantation. <i>Clinical Transplantation</i> , 2010, 24, 341-348.	1.6	64
152	Infections due to human herpesvirus 6 in solid organ transplant recipients. <i>Current Opinion in Organ Transplantation</i> , 2010, 15, 671-675.	1.6	20
153	R753Q Single-Nucleotide Polymorphism Impairs Toll-Like Receptor 2 Recognition of Hepatitis C Virus Core and Nonstructural 3 Proteins. <i>Transplantation</i> , 2010, 89, 811-815.	1.0	30
154	Innate immune genetic profile to predict infection risk and outcome after liver transplant. <i>Hepatology</i> , 2010, 52, 814-821.	7.3	11
155	Cytomegalovirus infection after liver transplantation. <i>Liver Transplantation</i> , 2010, 16, S45-S53.	2.4	8
156	A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection. <i>Transplant International</i> , 2010, 23, 506-513.	1.6	42
157	Immune-based therapies for cytomegalovirus infection. <i>Immunotherapy</i> , 2010, 2, 117-130.	2.0	28
158	New Developments in the Management of Cytomegalovirus Infection after Solid Organ Transplantation. <i>Drugs</i> , 2010, 70, 965-981.	10.9	178
159	Direct and indirect effects of cytomegalovirus: can we prevent them?. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2010, 28, 1-5.	0.5	42
160	Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 521-526.	9.1	329
161	Strategies for managing cytomegalovirus in transplant recipients. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1983-1997.	1.8	39
162	Current concepts on cytomegalovirus infection after liver transplantation. <i>World Journal of Hepatology</i> , 2010, 2, 325.	2.0	42

#	ARTICLE	IF	CITATIONS
163	Impact of human herpes virus 6 in liver transplantation. <i>World Journal of Hepatology</i> , 2010, 2, 345.	2.0	32
164	Human herpesvirus 6 infections after liver transplantation. <i>World Journal of Gastroenterology</i> , 2009, 15, 2561.	3.3	78
165	The R753Q Polymorphism Abrogates Toll-Like Receptor 2 Signaling in Response to Human Cytomegalovirus. <i>Clinical Infectious Diseases</i> , 2009, 49, e96-e99.	5.8	45
166	Case Report: <i>Capnocytophaga canimorsus</i> A Novel Pathogen for Joint Arthroplasty. <i>Clinical Orthopaedics and Related Research</i> , 2009, 467, 1634-1638.	1.5	21
167	Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. <i>Clinical Transplantation</i> , 2008, 22, 162-170.	1.6	158
168	Delayed-Onset Primary Cytomegalovirus Disease and the Risk of Allograft Failure and Mortality after Kidney Transplantation. <i>Clinical Infectious Diseases</i> , 2008, 46, 840-846.	5.8	233
169	Relationship between Toll-Like Receptor 2 Polymorphism and Cytomegalovirus Disease after Liver Transplantation. <i>Clinical Infectious Diseases</i> , 2007, 44, 1315-1320.	5.8	133
170	Prosthetic Joint Infection Due to Rapidly Growing Mycobacteria: Report of 8 Cases and Review of the Literature. <i>Clinical Infectious Diseases</i> , 2007, 45, 687-694.	5.8	120
171	Cytomegalovirus disease in solid organ transplant recipients: advances lead to new challenges and opportunities. <i>Current Opinion in Organ Transplantation</i> , 2007, 12, 610-617.	1.6	29
172	Polyomavirus Polymerase Chain Reaction as a Surrogate Marker of Polyomavirus-Associated Nephropathy. <i>Transplantation</i> , 2007, 84, 340-345.	1.0	124
173	Clinical Features and Outcomes of Delayed-onset Primary Cytomegalovirus Disease in Cardiac Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 1019-1024.	0.6	44
174	Valganciclovir for the treatment of cytomegalovirus retinitis in patients with AIDS. <i>Expert Review of Ophthalmology</i> , 2007, 2, 351-361.	0.6	4
175	An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance. <i>Liver Transplantation</i> , 2007, 13, 1422-1427.	2.4	26
176	Delayed-onset primary cytomegalovirus disease after liver transplantation. <i>Liver Transplantation</i> , 2007, 13, 1703-1709.	2.4	105
177	JC Virus Infection After Transplantation: Beyond the Classic Progressive Multifocal Leukoencephalopathy?. <i>Gastroenterology and Hepatology</i> , 2007, 3, 74-6.	0.1	1
178	Primary Cytomegalovirus Disease after Five Years of Antiviral Prophylaxis. <i>Transplantation</i> , 2006, 81, 137-138.	1.0	16
179	Stimulation of toll-like receptor 2 with bleomycin results in cellular activation and secretion of pro-inflammatory cytokines and chemokines. <i>Toxicology and Applied Pharmacology</i> , 2006, 210, 181-189.	2.8	35
180	Parvovirus B19 Infection after Transplantation: A Review of 98 Cases. <i>Clinical Infectious Diseases</i> , 2006, 43, 40-48.	5.8	216

#	ARTICLE	IF	CITATIONS
181	Clinical Utility of Cytomegalovirus (CMV) Serology Testing in High-risk CMV D+/R- Transplant Recipients. <i>American Journal of Transplantation</i> , 2005, 5, 1065-1070.	4.7	142
182	A Surveillance Study of Adenovirus Infection in Adult Solid Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2005, 5, 2555-2559.	4.7	118
183	Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. <i>American Journal of Health-System Pharmacy</i> , 2005, 62, S7-S13.	1.0	102
184	A Longitudinal Molecular Surveillance Study of Human Polyomavirus Viremia in Heart, Kidney, Liver, and Pancreas Transplant Patients. <i>Journal of Infectious Diseases</i> , 2005, 192, 1349-1354.	4.0	65
185	Nystatin Induces Secretion of Interleukin (IL)-1 $\beta$ , IL-8, and Tumor Necrosis Factor Alpha by a Toll-Like Receptor-Dependent Mechanism. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3546-3549.	3.2	30
186	Secretion of Proinflammatory Cytokines and Chemokines during Amphotericin B Exposure Is Mediated by Coactivation of Toll-Like Receptors 1 and 2. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 1617-1621.	3.2	73
187	Herpesvirus Infections in Solid Organ Transplant Patients at High Risk of Primary Cytomegalovirus Disease. <i>Journal of Infectious Diseases</i> , 2005, 192, 1331-1339.	4.0	109
188	Infections and allograft rejection - intertwined complications of organ transplantation. <i>Swiss Medical Weekly</i> , 2005, 135, 571-3.	1.6	27
189	Linezolid Therapy for Orthopedic Infections. <i>Mayo Clinic Proceedings</i> , 2004, 79, 1137-1144.	3.0	50
190	Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. <i>Expert Review of Anti-Infective Therapy</i> , 2004, 2, 27-41.	4.4	45
191	Management of CMV infection and disease in transplant patients. 27-29 February 2004. <i>Herpes: the Journal of the IHMF</i> , 2004, 11, 77-86.	0.3	34
192	Detection of simultaneous $\beta$ 2-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. <i>Clinical Transplantation</i> , 2003, 17, 114-120.	1.6	72
193	Lemierre Syndrome Variant: Necrobacillosis Associated With Inferior Vena Cava Thrombosis and Pulmonary Abscesses After Trauma-Induced Leg Abscess. <i>Mayo Clinic Proceedings</i> , 2003, 78, 1153-1156.	3.0	40
194	Dynamics of Cytomegalovirus Replication during Preemptive Therapy with Oral Ganciclovir. <i>Journal of Infectious Diseases</i> , 2003, 187, 1801-1808.	4.0	91
195	Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. <i>Herpes: the Journal of the IHMF</i> , 2003, 10, 60-5.	0.3	26
196	Selective Reactivation of Human Herpesvirus 6 Variant A Occurs in Critically Ill Immunocompetent Hosts. <i>Journal of Infectious Diseases</i> , 2002, 185, 110-113.	4.0	137
197	Role of the Laboratory in Diagnosis and Management of Cytomegalovirus Infection in Hematopoietic Stem Cell and Solid-Organ Transplant Recipients. <i>Journal of Clinical Microbiology</i> , 2002, 40, 746-752.	3.9	137
198	The Pathogenesis of Hepatitis C Virus Is Influenced by Cytomegalovirus. <i>Clinical Infectious Diseases</i> , 2002, 35, 974-981.	5.8	85

#	ARTICLE	IF	CITATIONS
199	Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transplantation, 2002, 8, 362-369.	2.4	223
200	The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation. Liver Transplantation, 2002, 8, 651-658.	2.4	83
201	The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation, 2002, 73, 968-973.	1.0	144
202	Cidofovir Treatment of Progressive Multifocal Leukoencephalopathy in a Patient Receiving Highly Active Antiretroviral Therapy. Mayo Clinic Proceedings, 2001, 76, 1171-1175.	3.0	39
203	Comparative Quantitation of Cytomegalovirus (CMV) DNA in Solid Organ Transplant Recipients with CMV Infection by Using Two High-Throughput Automated Systems. Journal of Clinical Microbiology, 2001, 39, 4472-4476.	3.9	71
204	Casirivimab-Imdevimab Treatment Is Associated with Reduced Rates of Hospitalization Among High-Risk Patients with Mild to Moderate Coronavirus Disease-19. SSRN Electronic Journal, 0, , .	0.4	2
205	Cytomegalovirus Infection in Transplantation. , 0, , 129-167.		1
206	Toll-Like Receptors: Novel Molecular Targets for Antiviral Immunotherapy. , 0, , 333-346.		0